Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;146(6):583-593.
doi: 10.1111/acps.13504. Epub 2022 Oct 12.

Twenty-year medication use trends in first-episode bipolar disorder

Juulia Poranen  1 , Aura Koistinaho  1 , Antti Tanskanen  1   2 , Jari Tiihonen  1   2   3 , Heidi Taipale  1   2   4 , Markku Lähteenvuo  1
Affiliations

Twenty-year medication use trends in first-episode bipolar disorder

Juulia Poranen et al. Acta Psychiatr Scand. 2022 Dec.

Abstract

Objectives: To study the medication use patterns in patients newly diagnosed with bipolar disorder (BD) in Finland during the past 20 years.

Methods: All persons diagnosed with BD between 1996 and 2018, aged 16-65 years, with no previous BD diagnosis were identified from nationwide Finnish registers (N = 26,395). The point prevalences of medication use were observed up until 5 years after the first diagnosis. Five sub-cohorts according to calendar year of first diagnosis were also formed and the prevalence of medication use was compared between sub-cohorts 3 months after diagnosis. Medication data were modeled with the PRE2DUP-method using dispensing data.

Results: The prevalence of overall medication use declined during the 5-year follow-up period in the total cohort. The highest prevalence of use was seen 3 months after diagnosis for the three main medication classes-antidepressants (40.8%), antipsychotics (30.8%) and mood stabilizers (29.2%). The prevalence of lithium use varied between 5.9% and 6.5% during the 5 years in the total cohort, and the lowest prevalence of use at 3 months was seen in sub-cohort diagnosed in 2016-2018 (4.1%) versus 12.1% in 1996-2000 sub-cohort. The prevalence of benzodiazepine use was between 12.4% and 13.5% and the prevalence of Z-drugs was between 7.3% and 7.9% during the 5 years. The prevalence of long-acting injectable antipsychotic (LAI) use was the highest in patients diagnosed in 2016-2018, although still only 0.8%.

Conclusions: (i) The use of antidepressants is too prevalent, (ii) the use of lithium is declining and needs to be increased, and (iii) LAIs are markedly underutilized as compared to their oral counterparts.

Keywords: antipsychotics; bipolar disorder; medication trends; mood stablizers; pharmacoepidemiology.

PubMed Disclaimer

Conflict of interest statement

Jari Tiihonen, Heidi Taipale and Antti Tanskanen have participated in research projects funded by grants from Janssen‐Cilag and Eli Lilly to their employing institution. Heidi Taipale reports personal fees from Janssen‐Cilag and Otsuka. Jari Tiihonen reports personal fees from Eli Lilly, Evidera, Janssen‐Cilag, Lundbeck, Mediuutiset, Otsuka, Sidera, and Suvovion; and is a consultant to Orion and HLS Therapeutics. Markku Lähteenvuo is a board member of Genomi Solutions Ltd., Nursie Health Ltd., and Springflux Ltd. has received honoraria from Sunovion, Orion Pharma, Lundbeck, Otsuka Pharma, Recordati, Janssen and Janssen‐Cilag and research funding from the Finnish Cultural Foundation and the Emil Aaltonen Foundation.

Figures

FIGURE 1
FIGURE 1
Prevalence of antipsychotic, antidepressant, anticonvulsant and lithium use from 3 months to 5 years after diagnoses of bipolar disorder. Note the change in x‐axis scale (quarter of the year during the first year and half of the year after the first year). The same person may have used more than one medication class.
FIGURE 2
FIGURE 2
Prevalence of medication use from 3 months to 5 years after diagnoses of bipolar disorder. Note the change in the x‐axis scale quarter of the year during the first year and half of the year after first year). The same person may have used more than one medication class. SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin‐norepinephrine reuptake inhibitors.
FIGURE 3
FIGURE 3
The prevalence of (A) antidepressant (AD), (B) antipsychotic (AP), and (C) mood stabilizer (MS) use 3 months after diagnoses in each sub‐cohort diagnosed in different years. SSRIs, selective serotonin reuptake inhibitors; SNRIs, serotonin‐norepinephrine reuptake inhibitors; LAI, Long‐acting injectable antipsychotics; More than one AD/AP/MS, use of two or more AD/AP/MS simultaneously.
See this image and copyright information in PMC

Comment in

References

    1. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primer. 2018;4:18008. doi:10.1038/nrdp.2018.8 - DOI - PubMed
    1. McIntyre RS, Berk M, Brietzke E, et al. Bipolar disorders. The Lancet. 2020;396(10265):1841‐1856. doi:10.1016/S0140-6736(20)31544-0 - DOI - PubMed
    1. Bauer M, Andreassen OA, Geddes JR, et al. Areas of uncertainties and unmet needs in bipolar disorders: clinical and research perspectives. Lancet Psychiatry. 2018;5(11):930‐939. doi:10.1016/S2215-0366(18)30253-0 - DOI - PubMed
    1. Baldessarini RJ, Tondo L, Vázquez GH. Pharmacological treatment of adult bipolar disorder. Mol Psychiatry. 2019;24(2):198‐217. doi:10.1038/s41380-018-0044-2 - DOI - PubMed
    1. Kishi T, Ikuta T, Matsuda Y, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta‐analysis of double blind randomized controlled trials. Mol Psychiatry. 2022;27(2):1136‐1144. doi:10.1038/s41380-021-01334-4 - DOI - PMC - PubMed

MeSH terms